Obligate and facultative anaerobic bacteria in targeted cancer therapy: Current strategies and clinical applications

Dróżdż, Mateusz; Makuch, Sebastian; Cieniuch, Gabriela; Woźniak, Marta; Ziółkowski, Piotr

doi:10.1016/j.lfs.2020.118296

Cited by 52 publications

(27 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, members of the genus Bi dobacterium, as bene cial bacteria, regulate hepatic and serum BA pro les primarily by reducing the levels of deoxycholic acid and increasing the levels of chenodeoxycholic acid and ursodeoxycholic acid. Furthermore, high levels of Bi dobacterium in the gut microbiome can suppress pro-in ammatory genes in the liver, achieving anticancer effects [40,41].…”

Section: Discussionmentioning

confidence: 99%

Gut Microbiome Analysis as a Non-Invasive Tool for the Early Diagnosis of Cholangiocarcinoma

Zhang

Jin

et al. 2021

SSRN Journal

View full text Add to dashboard Cite

BACKGROUNDThe liver-microbiome axis is implicated in the pathogenesis of hepatobiliary cancer, and the role of the gut microbiota in cholangiocarcinoma (CCA) remains unclear. METHODWe conducted a case-control study on the intestinal ora of 33 CCA patients and 47 cholelithiasis individuals. We performed 16S rRNA gene sequencing to identify disease-related gut microbiota and assess the potential of the intestinal microbiome as a non-invasive biomarker for CCA. RESULTWe found that gut microbiome of CCA patients had a signi cantly higher alpha diversity (Shannon and Observed species indices, p = 0.006 and p = 0.02, respectively) and an overall different microbial community composition (p = 0.032). The genus Muribaculaceae_unclassi ed was most strongly associated with CCA (p < 0.001). We put forward a disease predictive model including twelve intestinal microbiome genera distinguished CCA patients from CF patients with an area under curve (AUC) of approximately 0.93 (95%CI, 0.85-0.987). The forecasting performance of this model was better than CA19-9. Moreover, genera Ezakiella and Garciella were only observed among intrahepatic cholangiocarcinoma patients. Further, we assessed predicted functional modules alternations CCA patients and uncovered a microbiota pattern speci c to CCA. CONCLUSIONOur ndings provide evidence of the intestinal microbiome as a non-invasive biomarker for CCA.

show abstract

Section: Discussionmentioning

confidence: 99%

Gut Microbiome Analysis as a Non-Invasive Tool for the Early Diagnosis of Cholangiocarcinoma

Zhang

Jin

et al. 2021

SSRN Journal

View full text Add to dashboard Cite

show abstract

“…Lactobacillus is a genus of Gram-positive, rod-shaped bacteria inhabiting the intestinal microbiome of humans and other mammals. As one of the major probiotic bacterium in the intestine, the key role of this bacterium is to share lactic acid fermentation with other bacteria and further strengthen the intestinal barrier [125]. Lactobacillus plantarum (L. plantarum) is being studied for various clinical applications, including cancer treatment.…”

Section: Lactobacillus Sppmentioning

confidence: 99%

Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy

et al. 2021

View full text Add to dashboard Cite

Currently approximately 10 million people die each year due to cancer, and cancer is the cause of every sixth death worldwide. Tremendous efforts and progress have been made towards finding a cure for cancer. However, numerous challenges have been faced due to adverse effects of chemotherapy, radiotherapy, and alternative cancer therapies, including toxicity to non-cancerous cells, the inability of drugs to reach deep tumor tissue, and the persistent problem of increasing drug resistance in tumor cells. These challenges have increased the demand for the development of alternative approaches with greater selectivity and effectiveness against tumor cells. Cancer immunotherapy has made significant advancements towards eliminating cancer. Our understanding of cancer-directed immune responses and the mechanisms through which immune cells invade tumors have extensively helped us in the development of new therapies. Among immunotherapies, the application of bacteria and bacterial-based products has promising potential to be used as treatments that combat cancer. Bacterial targeting of tumors has been developed as a unique therapeutic option that meets the ongoing challenges of cancer treatment. In comparison with other cancer therapeutics, bacterial-based therapies have capabilities for suppressing cancer. Bacteria are known to accumulate and proliferate in the tumor microenvironment and initiate antitumor immune responses. We are currently well-informed regarding various methods by which bacteria can be manipulated by simple genetic engineering or synthetic bioengineering to induce the production of anti-cancer drugs. Further, bacterial-based cancer therapy (BBCT) can be either used as a monotherapy or in combination with other anticancer therapies for better clinical outcomes. Here, we review recent advances, current challenges, and prospects of bacteria and bacterial products in the development of BBCTs.

show abstract

“…The vesicular stomatitis virus (VSV) is known to have a particular affinity for hypoxic environments [279]. Several oncolytic bacterial species have innate hypoxic sensitivities, especially those that are anaerobic [223,280]. It is worth noting that many of the moieties employed in hypoxia-responsive nanoparticles have the potential to be applied in various forms through genetic modification of oncolytic bacteria to confer added specificity [281].…”

Section: Endogenous Environmentmentioning

confidence: 99%

The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors

et al. 2021

View full text Add to dashboard Cite

While many classes of chemotherapeutic agents exist to treat solid tumors, few can generate a lasting response without substantial off-target toxicity despite significant scientific advancements and investments. In this review, the paths of development for nanoparticles, oncolytic viruses, and oncolytic bacteria over the last 20 years of research towards clinical translation and acceptance as novel cancer therapeutics are compared. Novel nanoparticle, oncolytic virus, and oncolytic bacteria therapies all start with a common goal of accomplishing therapeutic drug activity or delivery to a specific site while avoiding off-target effects, with overlapping methodology between all three modalities. Indeed, the degree of overlap is substantial enough that breakthroughs in one therapeutic could have considerable implications on the progression of the other two. Each oncotherapeutic modality has accomplished clinical translation, successfully overcoming the potential pitfalls promising therapeutics face. However, once studies enter clinical trials, the data all but disappears, leaving pre-clinical researchers largely in the dark. Overall, the creativity, flexibility, and innovation of these modalities for solid tumor treatments are greatly encouraging, and usher in a new age of pharmaceutical development.

show abstract

Obligate and facultative anaerobic bacteria in targeted cancer therapy: Current strategies and clinical applications

Cited by 52 publications

References 123 publications

Gut Microbiome Analysis as a Non-Invasive Tool for the Early Diagnosis of Cholangiocarcinoma

Gut Microbiome Analysis as a Non-Invasive Tool for the Early Diagnosis of Cholangiocarcinoma

Bacterial-Based Cancer Therapy (BBCT): Recent Advances, Current Challenges, and Future Prospects for Cancer Immunotherapy

The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors

Contact Info

Product

Resources

About